Trial Profile

A Randomized, Double-blind, Placebo-controlled Clinical Trial, to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cell), in Healthy Elderly Aged 60 Years and Above

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 17 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SARS-COV-2 vaccine-inactivated-Sinovac-Biotech (Primary)
Indications COVID 2019 infections
Focus Adverse reactions; Pharmacodynamics
Sponsors Sinovac Biotech

Most Recent Events

09 Aug 2022 Status changed from active, no longer recruiting to completed.
01 Apr 2022 Interim Results from NCT04352608 and NCT04383574 evaluating Immunogenicity and safety of a third dose of CoronaVac and immune persistence of a two-dose schedule,published in The Lancet Infectious Diseases
16 Aug 2021 Planned End Date changed from 30 Jul 2021 to 30 Jul 2022.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com